Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Eli Lilly and Company
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 5 ans
A study to compare a new drug for Type 2 Diabetes to placebo (a placebo looks like the study drug but has no medicine) and to a treatment already available for Type 2 Diabetes
To demonstrate a dose-response relationship of once-weekly subcutaneous injections of LY2944876 on hemoglobin A1c (HbA1c) change from baseline, and from this dose-response relationship at 12 weeks det...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 5 ans
Comparison of Two Different Treatment Strategies in Patients with Major Depressive Disorder Not Exhibiting Improvement on Escitalopram Treatment: Early vs. Delayed Intervention Strategy
This study has two primary objectives: (1) to test the hypothesis that time to confirmed response is shorter in the early intervention strategy vs. the delayed intervention strategy, among patients id...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 5 ans
Evaluation of long term safety of LY2951742 in Patients with Migraine
To evaluate the long-term safety and tolerability of LY2951742 in patients suffering from migraine, with or without aura, for up to 1 year of treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 5 ans
A Phase 2 Study of Oral Enzastaurin HCl in Patients with Metastatic Colorectal Cancer
Main objective :To estimate the 6-month (24 weeks) progression-free survival for patients with metastatic CRC who are treated with enzastaurin.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 5 ans
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterol
The primary objective of this study is to assess the mean percentage change from baseline to week 16 in low-density lipoprotein cholesterol (LDL-C) measured using beta quantification with LY3015014 co...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Ltd
MAJ Il y a 5 ans
Treatment Strategies in Patients with Type 2 Diabetes Mellitus Not Achieving Glycemic Control while on Therapy with Premixed Insulin Analogues and Metformin: A Comparison of Insulin Lispro MM Intensive Mixture Therapy with Progressive Dose-Titration of Insulin Lispro LM or Biphasic Insulin Aspart 30/70
The primary objective of this study is to compare efficacy of two insulin treatment strategies in patients with type 2 diabetes who have inadequate glycemic control while treated with combination of ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 5 ans
A Study of LY3314814 in Participants With Mild Alzheimer's Disease Dementia (Daybreak)
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD as compared with placebo in patients with mild AD dementia
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 5 ans
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin with 5 FU/LV plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer
To compare Arm A versus Arm B in terms of PFS measured from the time of randomization after completing 6 cycles of first-line therapy for metastatic CRC: • Arm A: 5-FU/LV plus bevacizumab in combinat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 5 ans
Effect of LY450139, a γ-Secretase Inhibitor, on the Progression of Alzheimer’s Disease as Compared with Placebo
The primary objective of this study is to test the hypothesis that LY450139 given orally will slow the decline associated with AD as compared to placebo. Because of differences in regulatory requirem...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Ltd
MAJ Il y a 5 ans
A Study to Assess the Effect of Exenatide Treatment on Mean 24-hour Heart Rate in Patients with Type 2 Diabetes
To explore the effect of exenatide (BID) versus placebo (BID) treatment on change in mean 24-hour HR baseline to Week 12 of study drug exposure in patients with type 2 diabetes who have inadequate gly...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant